Squalene Epoxidase Metabolic Dependency Is a Targetable Vulnerability in Castration-Resistant Prostate Cancer

被引:28
|
作者
Xun Shangguan [1 ]
Ma, Zehua [2 ]
Yu, Minghao [1 ]
Ding, Jie [1 ]
Xue, Wei [2 ]
Qi, Jun [1 ]
机构
[1] Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Urol, Sch Med, Shanghai 200092, Peoples R China
[2] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Urol, Shanghai, Peoples R China
关键词
CHOLESTEROL-SYNTHESIS; ANDROGEN RECEPTOR; MONOOXYGENASE; INHIBITION; MECHANISMS; PATHWAY; PTEN; PROGRESSION; THERAPIES; ENZYME;
D O I
10.1158/0008-5472.CAN-21-3822
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Considering the dismal prognosis of castration-resistant prostate cancer (CRPC), it is critical to identify novel therapeutic targets in this disease. Malignant cells have metabolic dependencies distinct from their healthy counterparts, resulting in therapeutic vulnerabilities. Although PTEN and TP53 are the most frequently comutated or codeleted driver genes in lethal CRPC, the metabolic dependencies underlying PTEN/p53 deficiency-driven CRPC for therapeutic intervention remain largely elusive. In this study, PTEN/p53 deficient tumors were determined to be reliant on cholesterol metabolism. Moreover, PTEN/p53 deficiency transcriptionally upregulated squalene epoxidase (SQLE) via activation of sterol regulatory element-binding protein 2 (SREBP2). In addition, PTEN deficiency enhanced the protein stability of SQLE by inhibiting the PI3K/Akt/GSK3 beta-mediated proteasomal pathway. Consequently, SQLE increased cholesterol biosynthesis to facilitate tumor cell growth and survival. Pharmacologic blockade of SQLE with FR194738 profoundly suppressed the invasive program of CRPC. Collectively, these results demonstrate a synergistic relationship between SQLE and PTEN/p53 deficiency in CRPC development and progression. Therefore, pharmacologic interventions targeting SQLE may hold promise for the treatment of patients with CRPC. Significance: This study reveals PTEN and p53 deficiency confers a dependence on SQLE-mediated cholesterol metabolism, providing insights for new therapeutic strategies for treating castration-resistant prostate cancer.
引用
收藏
页码:3032 / 3044
页数:13
相关论文
共 50 条
  • [1] Asparagine Dependency Is a Targetable Metabolic Vulnerability in TP53-Altered Castration-Resistant Prostate Cancer
    Yoo, Young A.
    Quan, Songhua
    Yang, William
    Guo, Qianyu
    Rodriguez, Yara
    Chalmers, Zachary R.
    Dufficy, Mary F.
    Lackie, Barbara
    Sagar, Vinay
    Unno, Kenji
    Truica, Mihai I.
    Chandel, Navdeep S.
    Abdulkadir, Sarki A.
    CANCER RESEARCH, 2024, 84 (18) : 3004 - 3022
  • [2] DIETHYLSTILBESTROL IN CASTRATION-RESISTANT PROSTATE CANCER OESTROGENS IN CASTRATION-RESISTANT PROSTATE CANCER: BACK TO THE FUTURE?
    Sartor, Oliver
    BJU INTERNATIONAL, 2012, 110 (11B) : E736 - E736
  • [3] Darolutamide For Castration-Resistant Prostate Cancer
    Bastos, Diogo A.
    Antonarakis, Emmanuel S.
    ONCOTARGETS AND THERAPY, 2019, 12 : 8769 - 8777
  • [4] Immunotherapy for Castration-Resistant Prostate Cancer
    Sonpavde, Guru
    Kantoff, Philip W.
    UROLOGIC CLINICS OF NORTH AMERICA, 2012, 39 (04) : 465 - +
  • [5] Metastatic castration-resistant prostate cancer
    Henriques, Vanessa
    Wenzel, Mike
    Demes, Melanie-Christin
    Koellermann, Jens
    PATHOLOGE, 2021, 42 (04): : 431 - 438
  • [6] Chemotherapy for castration-resistant prostate cancer
    Berthold, D.
    ONKOLOGIE, 2011, 34 : 12 - 12
  • [7] Strategies in castration-resistant prostate cancer
    Bessede, Th
    PROGRES EN UROLOGIE, 2011, 21 : S68 - S71
  • [8] Abiraterone and castration-resistant prostate cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2013, 14 (02): : E48 - E48
  • [9] Diethylstilbestrol in castration-resistant prostate cancer
    Wilkins, Anna
    Shahidi, Mehdi
    Parker, Chris
    Gunapala, Ranga
    Thomas, Karen
    Huddart, Robert
    Horwich, Alan
    Dearnaley, David
    BJU INTERNATIONAL, 2012, 110 (11B) : E727 - E735
  • [10] The biology of castration-resistant prostate cancer
    Lian, Fei
    Sharma, Nitya V.
    Moran, Josue D.
    Moreno, Carlos S.
    CURRENT PROBLEMS IN CANCER, 2015, 39 (01) : 17 - 28